Organon & Co. has reached an agreement to sell its JADA® System to Laborie Medical Technologies Corp. for up to $465 million. The deal includes an upfront payment of $440 million at closing and a potential additional $25 million contingent on certain 2026 revenue targets. Approximately 100 employees will transition to Laborie as part of the transaction. The proceeds from the sale will be used to reduce Organon's debt and support future investments in women's health biopharma and other strategic initiatives. The transaction is expected to close in the first quarter of 2026, pending regulatory approvals and customary closing conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251107954738) on November 07, 2025, and is solely responsible for the information contained therein.